Among these, the PARPi Olaparib, approved in 2014 for germline BRCA1/2-mutated ovarian cancer and in 2019 for BRCA1/2-mutated PDAC, was the first agent to directly exploit DNA repair deficiencies in cancers [128]. This evidence concerns the gene BRCA1 and ovarian cancer.